Below is the current list of studies covered by the CIRB. It includes both Available to Open and Completed studies. Study documents approved after July 1, 2013 for all covered studies are available on the CTSU website.
To request documents approved before July 1, 2013, please contact the CIRB Helpdesk.
|Study Number||Lead Group||Study Title||CIRB||Study Status|
|10026||ETCTN||A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid||Adult CIRB - Early Phase Emphasis||Available to Open|
|10030||ETCTN||A phase 1 study of blinatumomab in combination with checkpoint inhibitor(s) of PD-1 (nivolumab) or both PD-1 (nivolumab) and CTLA-4 (ipilimumab) in patients with poor-risk; relapsed or refractory CD19+ precursor B-lymphoblastic leukemia||Adult CIRB - Early Phase Emphasis||Available to Open|
|10031||ETCTN||A Phase 1 Study of PARP inhibitor olaparib and HSP90 inhibitor AT13387 for treatment of advanced solid tumors with expansion in patients with recurrent epithelial ovarian; fallopian tube; peritoneal cancer or recurrent triple-negative breast cancer||Adult CIRB - Early Phase Emphasis||Completed|
|10042||ETCTN||A Phase II trial of AZD9291 (osimertinib) with or without bevacizumab in patients with EGFR mutation positive NSCLC and brain metastases||Adult CIRB - Early Phase Emphasis||Available to Open|
|10050||ETCTN||A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer harboring KRAS G12R Mutations||Adult CIRB - Early Phase Emphasis||Completed|
|10056||ETCTN||A Phase 2 Study of Talimogene Laherparepvec (T-VEC) and Radiation in Localized Soft Tissue Sarcoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10058||ETCTN||A Phase I Study of talimogene laheparepvec (TALIMOGENE LAHERPAREPVEC) with Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum||Adult CIRB - Early Phase Emphasis||Completed|
|10061||ETCTN||A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors||Adult CIRB - Early Phase Emphasis||Available to Open|
|10066||ETCTN||A Phase 1 / 2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma||Adult CIRB - Early Phase Emphasis||Available to Open|
|10067||ETCTN||A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy||Adult CIRB - Early Phase Emphasis||Available to Open|